Monoamines and their metabolites in plasma and lumbar cerebrospinal fluid of Chinese patients with Parkinson's disease.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Journal of Neurological Sciences

• Publication date

  1993-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0022-510X(93)90316-QPMID 8336158
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease

  1991cited by this paper
• Cerebrospinal fluid dopamine, norepinephrine, and epinephrine concentrations in Parkinson's disease correlated with clinical symptoms.

  1990cited by this paper
• Treatment of idiopathic parkinsonism with l-dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of l-dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa

  1989cited by this paper
• Catecholamines in CSF, plasma, and tissue after autologous transplantation of adrenal medulla to the brain in patients with Parkinson's disease.

  1989cited by this paper
• A new approach to biochemical evaluation of brain dopamine metabolism

  1988cited by this paper
• Cerebrospinal fluid homovanillic acid and parkinsonism in Huntington's disease

  1988cited by this paper
• Correlation of autonomic dysfunction to CSF concentrations of noradrenaline and 3-methoxy-4-hydroxyphenylglycol in Parkinson's disease.

  1987cited by this paper
• The Hamilton Rating Scale for Depression

  1986cited by this paper
• Effect of L-threo-3,4-dihydroxyphenylserine chronic administration on cerebrospinal fluid and plasma free 3-methoxy-4-hydroxy-phenylglycol concentration in patients with Parkinson's disease.

  1986cited by this paper
• Plasma catecholamine measurements in resting and stressed conscious rats, using high performance liquid chromatography with electrochemical detection.

  1985cited by this paper
• CSF monoamine metabolite levels in Alzheimer's and Parkinson's disease.

  1985cited by this paper
• CSF Monoamine Metabolites in Movement Disorders and Normal Aging

  1985cited by this paper
• CSF monamine metabolites in movement disorders and normal aging.

  1985cited by this paper
• Monoamine metabolites in human cerebrospinal fluid. HPLC/ED method

  1984cited by this paper
• 3‐O‐ methyldopa blocks dopa metabolism in rat corpus striatum

  1982cited by this paper
• Textbook of Adverse Drug Reactions

  1978cited by this paper
• CSF studies on the relationship between dopamine and 5-hydroxytryptamine in Parkinsonism and other movement disorders.

  1977cited by this paper
• The drug treatment of parkinsonism.

  1976cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper
• Serotonergic-dopaminergic interactions and extrapyramidal function.

  1974cited by this paper
• Serotonergic-dopaminergic interactions and extrapyramidal function.

  1974cited by this paper
• Review of Medical Pharmacology

  1972cited by this paper
• L‐Dopa induced changes in central monoamine neurons after peripheral decarboxylase inhibition *

  1970cited by this paper
• HOMOVANILLIC ACID AND 5‐HYDROXYINDOLEACETIC ACID IN THE CEREBROSPINAL FLUID OF PATIENTS WITH SENILE DEMENTIA, PRESENILE DEMENTIA AND PARKINSONISM

  1969cited by this paper
• The Association Between Quantitative Measures of Dementia and of Senile Change in the Cerebral Grey Matter of Elderly Subjects

  1968cited by this paper
• Parkinsonism

  1967cited by this paper
• TWENTY YEARS OF NORADRENALINE

  1966cited by this paper
• Twenty years of noradrenaline.

  1966cited by this paper

• Spatial metabolomics reveals the effects of Acanthopanax senticosus on region-specific alterations in neurotransmitters and metabolites levels in the brains of α-syn transgenic Parkinson’s disease model mice

  2025cites this paper
• How should we be using biomarkers in trials of disease modification in Parkinson’s disease?

  2023cites this paper
• Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease

  2021influential citation
• A Pilot Study of Changes in the Level of Catecholamines and the Activity of α-2-Macroglobulin in the Tear Fluid of Patients with Parkinson’s Disease and Parkinsonian Mice

  2021cites this paper
• Monoamine Levels and Parkinson’s Disease Progression: Evidence From a High-Performance Liquid Chromatography Study

  2021cites this paper
• CSF and PET biomarkers for noradrenergic dysfunction in neurodegenerative disease: A systematic review and meta‐analysis

  2021cites this paper
• Neuromodulation via the Cerebrospinal Fluid: Insights from Recent in Vitro Studies

  2018cites this paper
• Upgraded Methodology for the Development of Early Diagnosis of Parkinson’s Disease Based on Searching Blood Markers in Patients and Experimental Models

  2018cites this paper
• Homovanillic acid in CSF of mild stage Parkinson's disease patients correlates with motor impairment

  2017cites this paper
• Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l‐DOPA treatment and changes in levodopa‐induced dyskinesia

  2017cites this paper
• Adrenergic receptor-mediated modulation of striatal firing patterns.

  2016cites this paper
• Reduced plasma serotonin and 5-hydroxyindoleacetic acid levels in Parkinson's disease are associated with nonmotor symptoms.

  2015cites this paper
• Is elevated norepinephrine an etiological factor in some cases of Parkinson's disease?

  2014cites this paper
• Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease

  2014influential citation
• Serotonin Impairment in CSF of PD Patients, without an Apparent Clinical Counterpart

  2014cites this paper
• The Role of the Noradrenergic System and Its Receptors in Levodopa-Induced Dyskinesia

  2014cites this paper
• Biomarkers, mechanisms, and potential prevention of catecholamine neuron loss in Parkinson disease.

  2013cites this paper
• Cerebrospinal fluid biomarkers for neurodegenerative disorders

  2013cites this paper
• Cerebrospinal Fluid Catecholamine Levels as Predictors of Outcome in Subarachnoid Hemorrhage

  2012cites this paper
• Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson's disease and other synucleinopathies.

  2012cites this paper
• The Noradrenergic System is a Major Component in Parkinson’s Disease

  2011cites this paper
• Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment.

  2011cites this paper
• Bioanalytical inaccuracy: a threat to the integrity and efficiency of research.

  2010cites this paper
• Postural instability in Parkinson’s disease: the adrenergic hypothesis and the locus coeruleus

  2009cites this paper
• Cerebrospinal fluid metabolite and nigrostriatal dopaminergic function in Parkinson’s disease

  2009cites this paper
• Neurochemical biomarkers in the differential diagnosis of movement disorders

  2009cites this paper
• Biochemical alteration in cerebrospinal fluid precedes behavioral deficits in Parkinsonian rats induced by 6-hydroxydopamine.

  2009influential citation
• The dopaminergic neurotransmitter system is associated with aggression and agitation in frontotemporal dementia.

  2008cites this paper
• Drug-induced parkinsonism

  2006cites this paper
• Drug-induced parkinsonism

  2006cites this paper
• Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease

  2005cites this paper
• Cerebrospinal Fluid Catecholamine Levels in Japanese Encephalitis Patients with Movement Disorders

  2005cites this paper
• Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease

  2004cites this paper
• Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations

  2004cites this paper
• Significance and origin of DOPA, DOPAC, and dopamine-sulphate in plasma, tissues and cerebrospinal fluid.

  2004cites this paper
• Liquid chromatography with amperometric detection using functionalized multi-wall carbon nanotube modified electrode for the determination of monoamine neurotransmitters and their metabolites.

  2003cites this paper
• Orthostatic hypotension from sympathetic denervation in Parkinson’s disease

  2002cites this paper
• Serotonergic Decompensation in the Akinetic Expression of Parkinson's Disease

  2000cites this paper
• The validity of the Hamilton and Montgomery‐Åsberg depression rating scales as screening and diagnostic tools for depression in Parkinson's disease

  2000cites this paper
• Depression in Parkinson’s Disease

  1998cites this paper
• α2A‐adrenergic receptors are expressed by diverse cell types in the fetal primate cerebral wall

  1997cites this paper
• CSF somatostatin increase in patients with early parkinsonian syndrome

  1995cites this paper
• Impairment of blood-brain barrier function by serotonin induces desynchronization of spontaneous cerebral cortical activity: experimental observations in the anaesthetized rat.

  1995cites this paper
• High-performance liquid chromatographic analysis with electrochemical detection of biogenic amines using microbore columns.

  1995cites this paper
• Studies of dementia, depression, electrophysiology and cerebrospinal fluid monoamine metabolites in patients with Parkinson's disease.

  1995cites this paper
• Rapid assay of the monoamine content in small volumes of rat plasma.

  1994cites this paper
• Cerebrospinal monoamine metabolites and amino acid content in patients with parkinsonian syndrome and rats lesioned with MPP+

  1994cites this paper
• Gilles de la tourette's syndrome in twins: Clinical and neurochemical data

  1990cites this paper
• Parkinsonism Manifesting Depression as the First Sign

  1989cites this paper
• Author ' s personal copy

  year unknowncites this paper